Leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1/LIR1/ILT2) is an inhibitory receptor broadly expressed on leukocytes and recognizes HLA-class I and human cytomegalovirus UL18. LILRB1 is encoded within the leukocyte receptor complex on 19q13.4, previously implicated to be a susceptibility region to systemic lupus erythematosus (SLE). In this study, we screened for polymorphisms of LILRB1 and examined their association with SLE and rheumatoid arthritis (RA). In the 5 0 portion of LILRB1, three haplotypes containing four non-synonymous substitutions within the ligand-binding domains and two single nucleotide polymorphisms within the promoter region were identified and designated as PE01 -03. In the 3 0 portion, two haplotypes (CY01, 02 ) containing a non-synonymous substitution of the cytoplasmic region were identified. CY01 and 02 did not co-segregate with PE01 -03. Significant association with susceptibility to SLE or RA was not observed; however, among the subjects not carrying RA-associated HLA-DRB1 shared epitope (SE), LILRB1.PE01/01 diplotype was significantly associated with RA (odds ratio 2.05, P 5 0.019 and Pc 5 0.038). Gross difference was not observed in the crystal structures, thermostabilities and binding affinities to HLA-class I ligands among LILRB1.PE01 -03 haplotype products; however, surface expression of LILRB1 was significantly decreased in lymphocytes and monocytes from the carriers of PE01 haplotype. These findings demonstrated that LILRB1 is highly polymorphic and is associated with susceptibility to RA in HLA-DRB1 SE negative subjects, possibly by insufficient inhibitory signaling in leukocytes. In addition, these observations suggested that the polymorphisms of LILR family members may be substantially involved in the diversity of human immune responses.
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INTRODUCTION
Leukocyte immunoglobulin-like receptor [LILR, also known as LIR, immunoglobulin-like transcript (ILT ), CD85 or monocyte/macrophage inhibitory receptor (MIR )] family consists of 13 member genes including two pseudogenes (ILT9 and ILT10 ) (1 -4) . LILRs can be divided into three classes. Group A (LILRA1, -A2, -A4, ILT8 and LIR9m/ILT11) delivers positive signals by pairing with the Fc receptor common g chain, which contains an immunoreceptor tyrosine-based activation motif (ITAM). Group B (LILRB1, -B2, -B3, -B4 and -B5) contains two to four immunoreceptor tyrosine-based inhibitory motif (ITIM)-like sequences within the cytoplasmic region and inhibits cell activation by recruiting SHP-1 or SHIP. LILRA3 and LIR9s may be secreted as soluble receptors. The LILR gene family is located in the leukocyte receptor complex (LRC), which also contains a number of closely related immunoglobulin-like receptor genes such as killer cell immunoglobulin-like receptors (KIRs ) and FCAR on human chromosome 19q13.4 (5 -7) . This region has been suggested to be one of the candidate susceptibility regions for systemic lupus erythematosus (SLE) (8, 9) .
LILRB1 is broadly expressed on hematopoietic cells, including antigen presenting cells (1 -3,10) , and can bind to a variety of HLA-class I molecules and to cytomegalovirus UL18 through two membrane-distal extracellular domains (D1 and D2) (11 -13) . Although most KIRs recognize polymorphic epitopes within the a1 and a2 domains of HLAclass I molecules, the binding site for LILRB1 has been mapped to HLA-class I heavy chain a3 domain and b 2 -microglobulin (b2m) (13) (14) (15) . It is consistent with the broad-binding specificity of LILRB1, because the a3 domain is relatively conserved among HLA-class I molecules.
In mice, Pira and Pirb represent orthologs of activating and inhibitory human LILR, respectively (16, 17) . Mice lacking Pirb showed impaired dendritic cell maturation and increased Th2 responses (18) . Furthermore, it was recently reported that both PIR-A and PIR-B proteins bind to various mouse MHC class I molecules, and Pirb deficient mice showed exacerbated graft versus host disease (GVHD) (19) . These observations suggest that LILRs may be critically involved in the regulation of immune system in various aspects.
It has been demonstrated that KIR genes are highly polymorphic not only in the nucleotide sequences, but also in the number of loci (20, 21) . Association with KIR polymorphisms has been demonstrated for autoimmune diseases such as rheumatoid arthritis (RA) (22, 23) , psoriatic arthritis (24), type I diabetes (25) and psoriasis (26, 27) , as well as for the clinical course of HIV (28) or hepatitis C virus (29) infection.
It is thus probable that LILR genes are also polymorphic, and if this is the case, then functional polymorphisms of LILR genes may substantially be related to the diversity of immune response among individuals and to the susceptibility to diseases. To date, systematic screening of LILR polymorphisms has not been reported, except for LILRA3 (30) and LILRB4 (31) genes. In this study, we made an attempt to systematically screen for the polymorphisms of LILRB1 gene and to examine whether they are associated with the susceptibility to RA and SLE.
RESULTS

Identification of LILRB1 polymorphisms and haplotypes
Polymorphism screening of the entire length of LILRB1 revealed 17 single nucleotide polymorphisms (SNPs). Nine SNPs were within the coding region, six within the introns and two within the promoter region (Fig. 1) . Among the SNPs in the coding sequence, four encoded non-synonymous substitutions (L68P, A93T, I142T and S155I) were found within the putative ligand-binding domains (D1 and D2) and the other one (E625K) was found between the two ITIMlike motifs important for SHP-1 recruitment (32) .
Rather than testing the disease association of every identified SNP individually, we adopted a study design to experimentally define the major haplotypes in the Japanese population based on the segregation patterns in 31 families, to determine the diplotype configuration of each case and control by genotyping only the tag SNPs and to examine the association between the haplotypes and the disease. This design can greatly reduce the number of statistical comparisons involved, if the number of haplotypes is limited when compared with the number of SNPs.
The segregation patterns indicated that 12 SNPs from 2634A.G in the promoter region to c.464G.T (S155I) in exon 5 constitute three major haplotypes in Japanese, which were designated as LILRB1.PE01, LILRB1.PE02 and LILRB1.PE03 (PE for promoter and extracellular regions) ( Table 1) . These three haplotypes could account for all 124 haplotypes of the parents of 31 unrelated families. The haplotype frequencies among 62 unrelated parents were LILRB1.PE01: 47.6%, LILRB1.PE02: 42.7% and LILRB1. PE03: 9.7%.
In contrast, two SNPs in the exon 15 encoding the cytoplasmic region, c.1866C.T (L622L) and c.1873G.A (E625K), were completely co-segregated in the families and designated as LILRB1.CY01 (c.1866C -c.1873G) and LILRB1.CY02 (c.1866T -c.1873A) (CY for cytoplasmic region). These haplotypes did not co-segregate with LILRB1. PE01-03 haplotypes.
Association of LILRB1 polymorphisms with rheumatic diseases
We first compared the diplotype frequencies of LILRB1 between patients with RA or SLE and healthy controls. The diplotype frequencies were compatible with Hardy-Weinberg equilibrium. Significant association was observed neither in RA nor in SLE, although a tendency of increase in PE01/01 diplotype was observed in RA [x 2 ¼ 3.26, P ¼ 0.071, Pc ¼ 0.64, odds ratio (OR) ¼ 1.40, 95% confidence interval (CI): 0.97-2.03. Pc was derived by multiplying the P-value by 9, because association with RA was tested for six PE diplotypes and three CY diplotypes] ( Table 2) .
To detect a minor genetic risk more sensitively, we next examined the association of LILRB1 polymorphisms in individuals with and without the established susceptibility alleles of HLA-DRB1 separately. As previously described, striking association of HLA-DRB1 shared epitope (SE) with susceptibility to RA was present in our subjects (33) . SE encoding alleles present in the Japanese population are DRB1 Ã 0101, (Table 3) . This difference was not observed in the comparison between SE-positive RA and controls.
In the case of SLE, neither stratification by HLA-DRB1 Ã 1501, an established susceptibility gene in Japanese (34, 35) nor by the clinical characteristics of SLE (age at onset, nephropathy, CNS lupus, serositis, hypo-complementemia, anti-dsDNA and anti-Sm) resulted in a significant association of LILRB1 haplotypes (data not shown).
As LILRB1 molecule interacts with HLA-class I but not with class II and HLA-DRB1 is in linkage disequilibrium with HLA-class I, it was possible that primary genetic interaction exists between LILRB1 and HLA-class I alleles rather than DRB1. To examine such a possibility, LILRB1 haplotype frequency was examined in combination with HLA-B alleles. A modest association of LILRB1.PE01/01 with RA was detected between patients and healthy individuals without HLA-B54 (x 2 ¼ 3.86, P ¼ 0.05, OR ¼ 1.78, 95% CI: 1.00 -3.16), which is in linkage disequilibrium with
HLA-DRB1
Ã 0405, the most frequent allele constituting SE in Japanese. However, the association was weaker in the subjects without HLA-DRB1 SE, suggesting that HLA-DRB1, rather than HLA-B, is primarily responsible for the genetic interaction with LILRB1. Stratification by other HLA-B alleles did not reveal significant association with LILRB1 with RA.
Structure, stability and HLA-class I binding of LILRB1 haplotype products Because LILRB1.PE01 haplotype associated with RA contains four non-synonymous substitutions within the ligand-binding domains (D1D2), among which three (L68, I142 and S155) are unique to this haplotype, we postulated that structural and/or functional changes associated with the amino acid substitutions may be responsible for the susceptibility to RA. To test such a hypothesis, we prepared D1D2 polypeptides encoded by LILRB1.PE01, 02 and 03 haplotypes, and crystal structures, thermostability and binding affinity to an array of HLA-class I ligands were examined.
Crystal structures of all three haplotype products were determined by molecular replacement and did not reveal substantial difference, except for the polymorphic sites (Fig. 2) . The thermostabilities were also not significantly different among three haplotype products, with the melting temperatures of 62.48C (LILRB1.PE01), 59.08C (LILRB1.PE02) and 62.88C (LILRB1.PE03). The binding affinities to a wide range of HLA-class I were examined by means of surface plasmon resonance (SPR), using HLA-A11, -B35, -Cw4 and -G1 recombinant proteins as representative ligands of LILRB1. Substantial differences in the binding affinities with HLA-class I molecules were not observed among LILRB1 haplotype products ( Fig. 3 ; Table 4 ). Furthermore, affinities of two different monoclonal antibodies (mAbs) to LILRB1 were not substantially different among the haplotype products ( Table 4 ).
Association of surface expression level of LILRB1 with polymorphisms LILRB1.PE01 haplotype contains two SNPs in the promoter region, which are not present in other haplotypes. We therefore compared the expression levels of LILRB1 on the surface of peripheral blood lymphocytes and monocytes from 11 healthy individuals carrying LILRB1.PE01 and five non-carriers of LILRB1.PE01. Although most of the monocytes were found to express LILRB1, only a proportion of lymphocytes were stained positive, compatible with the LILRB1 expression on most of the B cells but only a subset of T and NK cells (3, 36) . The average mean fluorescence intensity (MFI) of LILRB1 was significantly weaker in the individuals with LILRB1.PE01 when compared with those without LILRB1.PE01, both in the lymphocytes (mean + SD, MFI 2.96 + 0.19 versus 3.22 + 0.25; P ¼ 0.03) and in the monocytes (mean + SD, MFI 8.36 + 1.65 versus 10.32 + 1.39; P ¼ 0.04) (Fig. 4A) . This difference was not caused by weaker affinity of mAb HP-F1 to LILRB1.PE01 product, because affinity of HP-F1 to LILRB1.PE01D1D2 protein was not weaker in the SPR analysis (Table 4) .
To examine whether the reduction of surface expression of LILRB1 is specifically observed in any of the T and B lymphocyte subsets, three-color flow cytometric analyses were conducted using mAbs against CD4, CD8, CD19 and CD27 on eight LILRB1.PE01 carriers and on five non-carriers. The representative profiles are shown in Figure 4B . LILRB1 expression was observed in most of the CD19þCD27þ (memory B cells) and CD19þCD272 (naïve B cells) with a comparable intensity (data not shown), as well as in a substantial proportion of CD8þ T cells, but only in a tiny fraction of Table 2 . Frequencies of LILRB1 haplotypes in Japanese patients with RA, SLE and healthy controls 
Non synonymous substitutions are shown in bold and each amino acid residue is described below. These haplotypes can be distinguished by the combination of c.203T.C and c.277G.A. 
DISCUSSION
In the present study, we identified a number of SNPs in the LILRB1 gene. Although the KIR loci have been known to be highly polymorphic (20, 21) , polymorphism screening has not previously been performed in most LILR genes in a systematic manner. This study demonstrated that LILRB1 gene is also highly polymorphic. We also demonstrated that a haplotype containing four amino acid substitutions within the ligand-binding domains and two promoter SNPs is associated with the susceptibility to RA in HLA-DRB1 SE negative individuals. Association of LILRA3 (ILT6 ) deficiency with multiple sclerosis has recently been reported (37) . Although disease-associated changes in the expression levels of LILR family genes in the tissues have been reported in some diseases including RA (38) , this is the first study to demonstrate the role of genomic polymorphisms of LILR family gene in the susceptibility to rheumatic diseases. Because only modest linkage disequilibrium is observed between polymorphisms of LILRB1 and adjacent genes (unpublished data), the polymorphism of LILRB1 appears to be primarily associated with RA. The crystal structure of D1D2 and binding affinity with HLA-class I molecules of LILRB1.PE01 protein did not show substantial difference when compared with those of LILRB1.PE02 and PE03 proteins, despite four non-synonymous substitutions in these domains. This is probably because these amino acid positions (L68P, A93T, I142T and S155I) are not in direct contact with HLA-class I a3 and b2m (13). Essentially, similar affinities to two different clones of LILRB1 mAbs also support that there is no gross structural difference among the three haplotype products. Note that LILRB1.PE01 protein loses a potential N-linked glycosylation signal (140N-141V-142T) present in LILRB1.PE02 and LILRB1.PE03 proteins due to the nonsynonymous substitution of position 142, the effect of which cannot be addressed in our recombinant protein system. In addition, LILRB1.PE01 protein has higher hydrophobicity than the others. The possibility that these changes might affect protein-protein interactions in vivo cannot be excluded. Furthermore, it is theoretically possible that alteration in the affinity with human cytomegalovirus UL18, or other unidentified ligands, is somehow involved in the susceptibility to RA. However, at this point, it is more likely that the decreased expression level of LILRB1, possibly related to the two SNPs in the promoter region and/or post-transcriptional regulation, results in insufficient inhibitory signaling and leads to autoimmunity and inflammation. Such a scenario needs to be tested in future functional analyses.
The precise regulation of the LILRB1 cell surface expression level has been suggested to be important for the control of immune responses. Mice deficient in Pirb, an ortholog of human LILRB1, exhibit augmented Th2 responses after immunization with T cell-dependent antigens, enhanced IgG and IgE production (18) and accelerated GVHD after transfer of allogeneic splenocytes (19) . These phenotypes are associated with augmented activation of dendritic cells and concomitant upregulation of activating PIR-A, which shares its ligands with PIR-B. These observations suggest that PIR-A and PIR-B play a role in the regulation of the thresholds for the activation of immune system, and PIR-B prevents excessive immune responses in a constitutive manner. The broad recognition of MHC class I molecules by LILRB1 might suggest its role for the maintenance of immunological tolerance. Thus, the lower expression level of LILRB1 might result in the autoimmune response once strong activating signals were transmitted through the activating receptors into the immune effector cells.
In the present study, significant association of LILRB1 was only detected in HLA-DRB1 SE negative RA patients. HLA-DRB1 SE is an established risk factor for RA confirmed in most of the populations and has been estimated to account for a substantial proportion of the genetic background of RA (39) . The reason for this differential association remains unclear. One possible explanation is that the contribution of LILRB1 polymorphisms is much weaker than that of HLA-DRB1 SE and becomes apparent only when the genetic effect of HLA-DRB1 SE is excluded. Another possibility is that LILRB1.PE01 product may interact differentially with some HLA-class I allele products, which are in linkage disequilibrium with HLA-DRB1. Although differences in the affinity to HLA-A11, -B35, -Cw4 and -G1 among LILRB1 allele products were not detected, possible change in the affinity to some of other HLA products cannot be excluded. However, as the LILRB1 binding site on HLA-class I (a3 and b2m) is conserved among alleles, such a possibility appears unlikely.
In the clinical settings, genetic risk factors for HLA-DRB1 SE negative RA have been largely unknown, although association of NRAMP1 (40) and PD-1 (PDCD1 ) (41) has been 
2474
Human Molecular Genetics, 2005, Vol. 14, No. 16
reported in such a group of patients. Our present observations may eventually provide valuable information for genetic diagnosis or prediction of disease progression in patients with arthritis lacking HLA-DRB1 SE.
There are some limitations in this study. There was a bias of sex ratio in the samples examined in the present study. However, as the frequencies of LILRB1 haplotypes were not significantly different between males and females, the results are essentially identical after adjustments. The evidence for association observed in this study is marginal and could have suffered from genetic heterogeneity of the subjects, if present. Although the possibility of population stratification has not been formally excluded for our case -control subjects, the Japanese population has been shown to be relatively homogeneous with respect to genetic background from HLA studies (42) , and indeed, in a recently published large-scale case -control association study in Japanese, where 830 patients with RA and 658 unrelated controls were analyzed for population stratification using 2069 tag SNPs distributed in autosomes, no evidence for population stratification was observed (43) . With respect to our case -control cohorts, we have conducted association studies on more than 20 genes distributed throughout the genome using partially overlapping subgroups of RA (n ¼ 101-382 patients each) and controls (n ¼ 207 -304 each) randomly chosen from the same cohorts, and no significant difference in the genotype frequencies was observed for most of the polymorphic sites (35) . Taken together, it seems unlikely that population stratification had a substantial impact on our findings. Nevertheless, our observations need to be confirmed by independent studies in the future.
Possible roles of LILR genes for human inflammatory or infectious diseases are beginning to emerge. LILRB2 and LILRA1 have been reported to recognize HLA-B27 free heavy chain implicated in seronegative spondylarthropaties (11) . In lepromatous leprosy lesions where Th2 cytokines are dominantly expressed, LILRs (LILRB5, -B3, -A2, and -A3), especially LILRA2, were shown to be upregulated, suggesting that LILR signaling can regulate Th1/Th2 balance (44) . Taken together with our observations indicating extensive polymorphism and disease association, it is suggested that diversity in LILR genes may be profoundly involved in the regulation of immune responses and also in the susceptibility to diseases. Studies on the polymorphisms of other LILR genes are underway.
MATERIALS AND METHODS
Patients and controls
Polymorphism screening was performed on genomic DNA from 18 unrelated Japanese healthy individuals. To determine major haplotypes of LILRB1 in Japanese, 31 unrelated families that consist of probands and their parents (93 individuals in total) were analyzed. Case -control association studies were carried out on 557 patients with RA (50 males and 507 females, 44.5 + 13.1 years), 169 patients with SLE (12 males and 157 females, 40.1 + 14.3 years) and 396 controls (211 males and 185 females, 34.1 + 10.4 years). The patients were recruited from Matsuta Clinic, Juntendo University Hospital and the University of Tokyo Hospital, the healthy controls at the University of Tokyo and Japanese Red Cross Central and Kanagawa Blood Centers, all from Tokyo and adjacent areas. The patients were diagnosed according to the classification criteria of American College of Rheumatology (45, 46) . This study was approved by the research ethics review committees of the participating institutes.
Genomic DNA was purified from the peripheral blood leukocytes from the patients and healthy individuals, using a QIAamp DNA blood mini kit (Qiagen, Hilden, Germany).
Polymorphism screening and haplotype determination
Polymorphism screening and haplotype determination were performed using Japanese family samples by polymerase chain reaction (PCR)-direct sequencing method. The primers were designed according to the genomic DNA sequence of human LILRB1 (GenBank accession no. AF189277). Because the genomic DNA sequences of LILR family genes are highly homologous, nested PCR was employed to achieve specific amplification of LILRB1. The entire length of LILRB1 gene (2820 upstream from the translation start site to þ528 downstream of the 3 0 end of exon 15) was amplified as two overlapping fragments by means of a long PCR using two primer sets. One primer set was placed within the promoter region (LILRB1-long1F: 5 0 -CTGCTCATGACATTGATGCT CTG-3 0 ) and exon 4 (LILRB1-long1R: 5 0 -CGCTACCAT AGTAACAGCGATAC-3 0 ) and the other was placed within exon 4 (LILRB1-long2F: 5 0 -GTATCGCTGTTACTATGGTA GCG-3 0 ) and at 3 0 flanking region of LILRB1 (LILRB1-long2R: 5 0 -ATTACAGGCACTGCCACCACAT-3 0 ). Both PCRs were performed in 25 ml reaction mixtures containing 2.5 U of LA Taq DNA polymerase (TAKARA, Otsu, Shiga, Japan), using a T-GRADIENT Thermocycler (Biometra GmbH, Göttingen, Germany). The amplification procedure consisted of initial denaturation at 968C for 3 min, 35 cycles of denaturation at 968C for 30 s, annealing at 568C for 30 s and extension at 728C for 2 min or 5 min 30 s for each fragment, followed by the last extension at 728C for 7 min.
Each first PCR product was divided into several overlapping segments for second PCR followed by direct sequencing. The Owing to the limited availability of the KY1 mAb, only one experiment was performed.
second amplification was performed using the primer sets described in Table 5 . Each second PCR was performed in 25 ml reaction mixture containing 1 U of AmpliTaq Gold DNA polymerase (Perkin-Elmer Applied Biosystems, Foster City, CA, USA), using a T-GRADIENT Thermocycler or a GeneAmp PCR system 9700 (Perkin-Elmer Applied Biosystems). The amplification condition consisted of initial denaturation at 968C for 10 min, 35 cycles of denaturation at 968C for 30 s, annealing at 568C for 30 s and extension at 728C for 40 s, followed by the last extension at 728C for 4 min. Fluorescence-based automated cycle sequencing of PCR products was performed using ABI 377, 310 or 3100 sequencer (ABI PRISM, Applied Biosystems) with the dye-terminator method, according to the manufacture's instructions (ABI PRISM dRhodamine Terminator Cycle Sequencing-Ready Reaction Kit or BigDye ver3.1 Cycle Sequencing-Ready Reaction Kit). Haplotypes were determined from the segregation patterns of detected polymorphisms among family members. Although the population-based analysis can only statistically elucidate the haplotype structure, this method can definitely determine the haplotypes from genotyping data of the families.
Genotyping
The three major haplotypes identified within the promoter and extracellular regions (LILRB1.PE01, 02 and 03 ) could be determined from the combination of two SNPs (c.203T.C and c.277G.A ). These 'tag SNPs' were genotyped by direct sequencing of the E fragment (LILRB1-EF-LILRB1-ER). 
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Determination of the haplotypes encompassing the cytoplasmic region, LILRB1.CY01 (c.1866C -c.1873G ) and LILRB1.CY02 (c.1866T -c.1873A ), was performed using PCR-single strand conformation polymorphism (SSCP) method. A 289 bp fragment (forward primer: 5 0 -GACAGGC AGATGGACACTGAGG-3 0 and reverse primer: 5 0 -TTCC AGACTCCATGGAGTGT-3 0 ) containing both polymorphic sites was amplified, and then, 1 ml of solution containing the PCR product mixed with 7 ml of denaturing solution (95% formamide, 20 mM EDTA, 0.05% bromphenol blue, 0.05% xylene cyanol FF) was applied to polyacrylamide gel (acrylamide: bisacrylamide ¼ 49: 1) after denaturation and immediate cooling on ice. Electrophoresis was carried out in 0.5 Â BE [45 mM Tris-borate (pH 8.0), 1 mM EDTA] under constant current of 20 mA/gel, 208C for 90 min in 10% polyacrylamide gel using a minigel electrophoresis apparatus with a constant temperature control system (90 Â 80 Â 1 mm 3 , AE-8450, AB-1600 and AE-6370; ATTO, Tokyo, Japan). Single-strand DNA fragments in the gel were visualized by silver staining (Daiichi Chemicals, Tokyo, Japan).
Association was statistically analyzed using StatView-J5.0 (SAS Institute Inc., Cary, NC, USA). x 2 -tests were used to analyze association of the LILRB1 polymorphisms with susceptibility to RA and SLE. Hardy -Weinberg equilibrium was estimated from typing results using the EH program (47, 48) . P-values were corrected for multiple testing by Bonferroni correction. Specifically, for the association of LILRB1 diplotype frequencies with RA (Table 2) , the P-value was multiplied by 9, because independent tests were performed for six PE and three CY diplotypes. For the analysis of LILRB1.PE01/01 diplotype with RA stratified by HLA-DRB1 SE (Table 3) , the P-value was multiplied by 2, because two comparisons (LILRB1.PE01/01þ versus 2 in HLA-DRB1 SE carriers, LILRB1.PE01/01 þ versus 2 in HLA-DRB1 SE non-carriers) were performed.
HLA-DRB1 and HLA-B allele typing was performed using PCR-microtiter plate hybridization assay (33, 49) . -9F  CCTCATCCTCCGACATCGA  ex10  LILRB1-9R  GGAAGAAGGACAGAGCCTC  int10  10  LILRB1-10F  GAACATGGAGGCAGGAGTGT  int10  LILRB1-10R  TGAGATGATCTCACCCTGAG  int12  11  LILRB1-11F  TGAGAGGAAGAGGTGACCAG  int12  LILRB1-11R  CCACCGTGACGATGCTGAG  int13  12  LILRB1-12F  TCCTGGTGCCAGATCTAATC  int13  LILRB1-12R  GTTCCTTACAGCACGTTGCA  int13  13  LILRB1-13F  CCTGAGCTCACCTCGTGG  int13  LILRB1-13R  GTCAATTTTCCTCACTGTTCC  int13  14  LILRB1-14F  GATTCCATCGGGAAAGGGAT  int13  LILRB1-14R  TTCCAGACTCCATGGAGTGT  ex15  15  LILRB1-15F  TCTACGCCACTCTGGCCATC  ex15  LILRB1-15R  AGGCACTGCCACCACATCCA  3 As the amino acid sequence of the ILT2D1D2 turned out to be the LILRB1.PE03 haplotype product, expression vectors of LILRB1.PE01D1D2 and LILRB1.PE02D1D2 were prepared from pGEMILT2D1D2 vector using ordinary mutagenesis methods. Then, the LILRB1D1D2 proteins were expressed and purified as described earlier.
Soluble biotinylated HLA-A Ã 1101 (with peptide AIFQSSMTK), HLA-B Ã 3501 (with peptide IPLTEEAEL), HLA-Cw Ã 0401 (with peptide QYDDAVYKL) and HLA-G1 (with peptide RIIPRHLQL) were prepared as described (15) .
Crystallization and data collection
The LILRB1.PE01 and LILRB1.PE02 D1D2 proteins were crystallized from the mixture of 2 ml of the protein (5 mg/ml) and 1 ml of 0.595 M sodium potassium tartrate, 0.085 M Tris -HCl (pH 8.5) and 15% ethylene glycol at 208C by hanging drop method. Data were collected at 100 K at SPring-8 BL38B2 and BL41XU. The LILRB1.PE01 crystals belong to the space group of P2 1 (50) . The structures were determined by molecular replacement with the initial model of LILRB1.PE03 structure (PDB accession no. 1UFU) (unpublished data). The LILRB1.PE01 and LILRB1.PE02 D1D2 structures were refined using CNS (51) with 20.0 -2.75 and 8.0-1.8 Å reflections, respectively. The R free and R work of the final models were 29.5 and 25.0% for LILRB1.PE01 and 23.9 and 20.5% for LILRB1.PE02, respectively. The PDB accession nos for LILRB1.PE01 and LILRB1.PE02 D1D2 structures are 1VDG and 1UGN, respectively.
Surface plasmon resonance
In order to examine the interactions between recombinant LILRB1 D1D2 proteins and MHC class I complexes, SPR experiments were performed using a BIAcore2000 (BIAcore AB, St Albans, UK).
The biotinylated HLA-class I molecules and control biotinylated bovine serum albumin (BSA) were immobilized on the research-grade CM5 chip (BIAcore), onto which streptavidin was covalently coupled. Soluble D1D2 protein of each haplotype, after its buffer was exchanged to HBS-EP [10 mM HEPES (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% surfactant P20], was injected over the chip at 258C. The binding response at each concentration was calculated by subtracting the equilibrium response measured in the control flow cell from the response in the HLA-class I flow cell.
Kinetic constants were derived by using the curve-fitting facility of the BIAEVALUATION 3.0 program (BIAcore) to fit rate equations derived from the simple 1 : 1 Langmuir binding model (A þ B $ AB ). Other curve fittings were performed by ORIGIN 5 (Microcal Software, Northampton, MA, USA). Affinity constants (Kd ) were derived by Scatchard analysis or by non-linear curve fitting of the standard Langmuir binding isotherm.
Binding affinity assays between LILRB1D1D2 proteins and anti-LILRB1 (CD85j/ILT2) mAbs, HP-F1 (Beckman Coulter, Fullerton, CA, USA) and KY1 (36) were performed similarly, except that the mAbs and control BSA were immobilized onto the CM5 chip directly.
Circular dichroism
Recombinant LILRB1 D1D2 proteins were diluted to 10 mM in phosphate-buffered saline. In order to compare the thermostability of each LILRB1 D1D2 protein, circular dichroism (CD) spectroscopy was performed with JASCO-J720 spectropolarimeter (Jasco, Tokyo, Japan). The thermostabilities of the LILRB1 D1D2 proteins were analyzed by monitoring the change in the CD value at 217 nm as a function of temperature determined by preliminary experiment. During the alteration of temperature from 30 to 908C at a constant heating rate (0.258C/min), the changes of the secondary structure of LILRB1 (mainly b-sheet) are detected as CD values.
Flow cytometric analysis
Surface expression intensity of LILRB1 in peripheral blood leukocytes was examined in 16 healthy controls (11 with LILRB1.PE01 and five without LILRB1.PE01 ), using PEconjugated anti-LILIRB1, HP-F1 (Beckman Coulter). Differences in the MFIs of LILRB1-expressing lymphocytes and monocytes were compared between individuals with and without LILRB1.PE01 haplotype. In order to examine the LILRB1 expression level on the subsets of T and B lymphocytes, three-color analyses were performed using FITCconjugated anti-CD19, PC5-conjugated anti-CD27 mAbs for B cells and FITC-conjugated anti-CD4, PC5-conjugated anti-CD8 mAbs for T cells (Beckman Coulter). The differences were statistically analyzed using Mann -Whitney's U-test and Student's t-test.
